Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes
Ovarian cancer is the eighth most common neoplasm in women with a high mortality rate mainly due to a marked propensity for peritoneal spread directly at diagnosis, as well as tumor recurrence after radical surgical treatment. Treatments for peritoneal metastases have to be designed from a patient’s...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/23/6010 |
| _version_ | 1797463511379476480 |
|---|---|
| author | Daniele Marrelli Luca Ansaloni Orietta Federici Salvatore Asero Ludovico Carbone Luigi Marano Gianluca Baiocchi Marco Vaira Federico Coccolini Andrea Di Giorgio Massimo Framarini Roberta Gelmini Carmen Palopoli Fabio Accarpio Anna Fagotti |
| author_facet | Daniele Marrelli Luca Ansaloni Orietta Federici Salvatore Asero Ludovico Carbone Luigi Marano Gianluca Baiocchi Marco Vaira Federico Coccolini Andrea Di Giorgio Massimo Framarini Roberta Gelmini Carmen Palopoli Fabio Accarpio Anna Fagotti |
| author_sort | Daniele Marrelli |
| collection | DOAJ |
| description | Ovarian cancer is the eighth most common neoplasm in women with a high mortality rate mainly due to a marked propensity for peritoneal spread directly at diagnosis, as well as tumor recurrence after radical surgical treatment. Treatments for peritoneal metastases have to be designed from a patient’s perspective and focus on meaningful measures of benefit. Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery with regional chemotherapy, has been proposed to treat advanced ovarian cancer. Preliminary results to date have shown promising results, with improved survival outcomes and tumor regression. As knowledge about the disease process increases, practice guidelines will continue to evolve. In this review, we have reported a broad overview of advanced ovarian cancer management, and an update of the current evidence. The future perspectives of the Italian Society of Surgical Oncology (SICO) are discussed conclusively. |
| first_indexed | 2024-03-09T17:51:46Z |
| format | Article |
| id | doaj.art-d89069792ce4414ea77e46308152391d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T17:51:46Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d89069792ce4414ea77e46308152391d2023-11-24T10:42:18ZengMDPI AGCancers2072-66942022-12-011423601010.3390/cancers14236010Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study PurposesDaniele Marrelli0Luca Ansaloni1Orietta Federici2Salvatore Asero3Ludovico Carbone4Luigi Marano5Gianluca Baiocchi6Marco Vaira7Federico Coccolini8Andrea Di Giorgio9Massimo Framarini10Roberta Gelmini11Carmen Palopoli12Fabio Accarpio13Anna Fagotti14Unit of General Surgery and Surgical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, ItalyUnit of General Surgery San Matteo Hospital, 27100 Pavia, ItalyPeritoneal Tumors Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, ItalyUnit of Surgical Oncology, Soft Tissue Tumors, Department of Oncology, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi, 95123 Catania, ItalyUnit of General Surgery and Surgical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, ItalyUnit of General Surgery and Surgical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, ItalyDepartment of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili, 25123 Brescia, ItalyCandiolo Cancer Institute, FPO–IRCCS, Candiolo, 10060 Torino, ItalyGeneral, Emergency and Trauma Surgery, Pisa University Hospital, 56122 Pisa, ItalySurgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli–IRCCS, 00168 Rome, ItalySurgery and Advanced Oncological Therapy Unit, Ospedale GB. Morgagni-L. Pierantoni, AUSL Forlì, 47121 Forlì-Cesena, ItalyUnit of Emergency General Surgery and Surgical Oncology, AOU Policlinico di Modena, 41125 Modena, ItalyUnit of PSG and OBI, Azienda Ospedaliera Universitaria G. Martino, 98124 Messina, ItalyCRS and HIPEC Unit, Pietro Valdoni, Umberto I Policlinico di Roma, 00161 Roma, ItalyUnit of Ovarian Carcinoma, Fondazione Policlinico Universitario A. Gemelli–IRCCS, 00168 Rome, ItalyOvarian cancer is the eighth most common neoplasm in women with a high mortality rate mainly due to a marked propensity for peritoneal spread directly at diagnosis, as well as tumor recurrence after radical surgical treatment. Treatments for peritoneal metastases have to be designed from a patient’s perspective and focus on meaningful measures of benefit. Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery with regional chemotherapy, has been proposed to treat advanced ovarian cancer. Preliminary results to date have shown promising results, with improved survival outcomes and tumor regression. As knowledge about the disease process increases, practice guidelines will continue to evolve. In this review, we have reported a broad overview of advanced ovarian cancer management, and an update of the current evidence. The future perspectives of the Italian Society of Surgical Oncology (SICO) are discussed conclusively.https://www.mdpi.com/2072-6694/14/23/6010advanced ovarian cancerperitoneal metastasesneoadjuvant chemotherapyhyperthermic intraperitoneal chemotherapycytoreductive surgery |
| spellingShingle | Daniele Marrelli Luca Ansaloni Orietta Federici Salvatore Asero Ludovico Carbone Luigi Marano Gianluca Baiocchi Marco Vaira Federico Coccolini Andrea Di Giorgio Massimo Framarini Roberta Gelmini Carmen Palopoli Fabio Accarpio Anna Fagotti Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes Cancers advanced ovarian cancer peritoneal metastases neoadjuvant chemotherapy hyperthermic intraperitoneal chemotherapy cytoreductive surgery |
| title | Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes |
| title_full | Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes |
| title_fullStr | Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes |
| title_full_unstemmed | Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes |
| title_short | Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes |
| title_sort | cytoreductive surgery crs and hipec for advanced ovarian cancer with peritoneal metastases italian psm oncoteam evidence and study purposes |
| topic | advanced ovarian cancer peritoneal metastases neoadjuvant chemotherapy hyperthermic intraperitoneal chemotherapy cytoreductive surgery |
| url | https://www.mdpi.com/2072-6694/14/23/6010 |
| work_keys_str_mv | AT danielemarrelli cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT lucaansaloni cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT oriettafederici cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT salvatoreasero cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT ludovicocarbone cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT luigimarano cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT gianlucabaiocchi cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT marcovaira cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT federicococcolini cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT andreadigiorgio cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT massimoframarini cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT robertagelmini cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT carmenpalopoli cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT fabioaccarpio cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes AT annafagotti cytoreductivesurgerycrsandhipecforadvancedovariancancerwithperitonealmetastasesitalianpsmoncoteamevidenceandstudypurposes |